1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Latin American Pharmaceutical Market Outlook 2015-2025

Latin American Pharmaceutical Market Outlook 2015-2025

  • September 2015
  • -
  • Visiongain
  • -
  • 140 pages

Report Details
What can be expected from the Latin American pharmaceutical market? Which areas are going to grow at the fastest rates? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 140-page report provides 121 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.

See revenue forecasts for the leading international markets
How will leading national markets perform to 2025? Our study forecasts revenues in national markets including by product class for the following countries:
- Brazil
- Mexico
- Venezuela
- Argentina
- Colombia
- Chile

Leading companies and potential for market growth
Overall revenue for the Latin American pharmaceutical market will reach $87.29bn in 2018, our work forecasts. We predict strong revenue growth through to 2025. The ageing population in many of the region’s largest markets will combine with increasing investment in national health care systems to drive sales to 2025.

Our work analyses the key companies in the market. See visiongain’s analysis of 5 leading companies, including these:
- Sanofi
- EMS
- Novartis
- Pfizer
- Bayer

A company profile gives you the following information where available:
- Historical revenues from 2013 to 2014
- Discussion of a company’s activities and outlook
- Brief assessment of the companies Latin American strategy

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the Latin American pharmaceutical industry?
Our new report discusses issues and events affecting the Latin American pharmaceutical market. You will find discussions, including qualitative analyses:
- Highly diverse region needing strong knowledge of each national market
- Quickly evolving regulatory environment
- Economic weaknesses encouraging innovation

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Latin American Pharmaceutical Market Outlook 2015-2025 report helps you
In summary, our 140-page report gives you the following knowledge:
- Revenue forecasts to 2025 for the Latin American pharmaceutical market – discover the industry’s prospects, finding promising places for investments and revenues
- Revenue forecasts to 2025 for the leading regional markets – Brazil, Mexico, Venezuela, Argentina, Colombia, Chile
- Economic situation across the nations of Latin America – Understand the pressures faced across the region and how to achieve growth in an increasingly challenging environment
- Assessment of 5 leading companies – analysis of Latin American results and strategies
- Discussion of what stimulates and restrains companies and the market
- Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your resea

Table Of Contents

Latin American Pharmaceutical Market Outlook 2015-2025
Table of Contents
1. Report Overview
1.1 Latin American Pharmaceutical Market: Overview
1.2 Latin American Pharmaceutical Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Study
1.6 Who is This Investigation For?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQs)
1.9 Some Associated Reports
1.10 About visiongain

2. Introduction to the Latin American Pharmaceutical Market
2.1 Introduction to the Global Pharmaceutical Market
2.2 The Latin American Pharmaceutical Market 2014
2.2.1 Definition of Latin America
2.3 Regional Trade Bodies and Intergovernmental Organisations
2.3.1 Mercado Comun del Sur/Mercado Comum do Sul (Mercosur)
2.3.2 The Andean Community (CAN)
2.3.3 The Union of South American Nations (USAN)
2.3.4 The Pacific Alliance
2.3.5 Bolivarian Alliance for the Peoples of Our America (ALBA)

3. The Latin American Pharmaceutical Market, 2015-2025
3.1 The Latin American Pharmaceutical Market Forecast, 2015-2025
3.2 Factors Affecting the Latin American Pharmaceutical Market
3.2.1 Population Growth and Ageing
3.2.2 Economic Conditions
3.2.3 Trans-Pacific Partnership (TPP)
3.3 The Latin American Pharmaceutical Market Breakdown, 2015-2025
3.3.1 The Latin American Generic Drugs Market Forecast, 2015-2025
3.3.2 The Latin American OTC Market Forecast, 2015-2025
3.3.3 The Latin American Biosimilars Market Forecast, 2015-2025
3.3.4 The Latin American Originator Drugs Market Forecast, 2015-2025
3.4 SWOT Analysis of the Latin American Pharmaceutical Market, 2015-2025
3.4.1 Strengths
3.4.1.1 One of the Quickest Growing Markets Globally
3.4.1.2 Increasing Incidence of Chronic Diseases
3.4.1.3 Ageing Population
3.4.1.4 Increasing Investment in Health Care Systems
3.4.2 Weaknesses
3.4.2.1 Poor Economic Performance and Devalued Currencies
3.4.2.2 Weak Regulation
3.4.2.3 Weak IP Protection
3.4.3 Opportunities
3.4.3.1 Emerging Biosimilars Market
3.4.3.2 Regional Pharmaceutical Companies Could Expand Outside Latin America
3.4.3.3 Increased Trade Liberalisation Could Open More Markets
3.4.4 Threats
3.4.4.1 Pharmaceutical Companies from Other Emerging Markets Could Challenge Regional Firms
3.4.4.2 Increased Protectionist Measures Could Severely Harm the Industry
3.4.4.3 Further Economic Problems and Currency Devaluations Possible

4. Latin American National Markets, 2015-2025
4.1 Latin American National Markets, 2014
4.2 Latin American National Pharmaceutical Market Forecasts, 2015-2025
4.3 Leading National Markets as Shares of the Latin American Pharmaceutical Market
4.3.1 Leading National Markets as Shares of the Latin American Pharmaceutical Market, 2014
4.3.2 Leading National Markets as Shares of the Latin American Pharmaceutical Market, 2020
4.3.3 Leading National Markets as Shares of the Latin American Pharmaceutical Market, 2025

5. The Brazilian National Pharmaceutical Market, 2015-2025
5.1 The Brazilian National Pharmaceutical Market, 2014
5.2 The Brazilian National Pharmaceutical Sub-Market Forecasts, 2015-2025
5.2.1 The Brazilian National Pharmaceutical Market Forecast, 2015-2025
5.2.2 The Brazilian Generic Drugs Market Forecast, 2015-2025
5.2.3 The Brazilian OTC Market Forecast, 2015-2025
5.2.4 The Brazilian Biosimilars Market Forecast, 2015-2025
5.2.5 The Brazilian Originator Drugs Market Forecast, 2015-2025
5.3 The Brazilian National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations

6. The Mexican National Pharmaceutical Market, 2015-2025
6.1 The Mexican National Pharmaceutical Market, 2014
6.2 The Mexican National Pharmaceutical Sub-Markets Forecasts, 2015-2025
6.2.1 The Mexican National Pharmaceutical Market Forecast, 2015-2025
6.2.2 The Mexican Generic Drugs Market Forecast, 2015-2025
6.2.3 The Mexican OTC Market Forecast, 2015-2025
6.2.4 The Mexican Biosimilars Market Forecast, 2015-2025
6.2.5 The Mexican Originator Drugs Market Forecast, 2015-2025
6.3 The Mexican National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations

7. The Venezuelan National Pharmaceutical Market, 2015-2025
7.1 The Venezuelan National Pharmaceutical Market, 2014
7.2 The Venezuelan National Pharmaceutical Market Breakdown Forecast, 2015-2025
7.2.1 The Venezuelan National Pharmaceutical Market Forecast, 2015-2025
7.2.2 The Venezuelan Generic Drugs Market Forecast, 2015-2025
7.2.3 The Venezuelan OTC Market Forecast, 2015-2025
7.2.4 The Venezuelan Biosimilars Market Forecast, 2015-2025
7.2.5 The Venezuelan Originator Drugs Market Forecast, 2015-2025
7.3 The Venezuelan National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations

8. The Argentine National Pharmaceutical Market, 2015-2025
8.1 The Argentine National Pharmaceutical Market, 2014
8.2 The Argentine National Pharmaceutical Market Breakdown, 2015-2025
8.2.1 The Argentine National Pharmaceutical Market Forecast, 2015-2025
8.2.2 The Argentine Generic Drugs Market Forecast, 2015-2025
8.2.3 The Argentine OTC Market Forecast, 2015-2025
8.2.4 The Argentine Biosimilars Market Forecast, 2015-2025
8.2.5 The Argentine Originator Drugs Market Forecast, 2015-2025
8.3 The Argentine National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations

9. The Colombian National Pharmaceutical Market, 2015-2025
9.1 The Colombian National Pharmaceutical Market, 2014
9.2 The Colombian National Pharmaceutical Market Breakdown, 2015-2025
9.2.1 The Colombian National Pharmaceutical Market Forecast, 2015-2025
9.2.1.1 Economic Growth and Financial Constraints
9.2.1.2 Introduction of the Statutory Health Law
9.2.2 The Colombian Generic Drugs Market Forecast, 2015-2025
9.2.3 The Colombian OTC Market Forecast, 2015-2025
9.2.4 The Colombian Biosimilars Market Forecast, 2015-2025
9.2.5 The Colombian Originator Drugs Market Forecast, 2015-2025
9.3 The Colombian National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations

10. The Chilean National Pharmaceutical Market, 2015-2025
10.1 The Chilean National Pharmaceutical Market, 2014
10.1.1 The Chilean Health Care System
10.1.2 Majority of Generic Revenue from Branded Generics
10.2 The Chilean National Pharmaceutical Market Breakdown, 2015-2025
10.2.1 The Chilean National Pharmaceutical Market Forecast, 2015-2025
10.2.2 The Chilean Generic Drugs Market Forecast, 2015-2025
10.2.3 The Chilean OTC Market Forecast, 2015-2025
10.2.4 The Chilean Biosimilars Market Forecast, 2015-2025
10.2.5 The Chilean Originator Drugs Market Forecast, 2015-2025
10.3 The Chilean National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations

11. The Rest of the Latin American Pharmaceutical Market, 2015-2025
11.1 The Rest of the Latin American Pharmaceutical Market, 2014
11.2 The Rest of the Latin American Pharmaceutical Market Breakdown, 2015-2025
11.2.1 The Rest of the Latin American Pharmaceutical Market Forecast, 2015-2025
11.2.2 The Rest of the Latin American Generic Drugs Market Forecast, 2015-2025
11.2.3 The Rest of the Latin American OTC Market Forecast, 2015-2025
11.2.4 The Rest of the Latin American Biosimilars Market Forecast, 2015-2025
11.2.5 The Rest of the Latin American Originator Drugs Market Forecast, 2015-2025
11.3 Accounting for Currency Fluctuations in the Rest of Latin America

12. Top Five Pharmaceutical Companies in Latin America
12.1 Sanofi S.A
12.2 EMS S.A
12.3 Novarits
12.4 Pfizer
12.5 Bayer

13. Conclusions
13.1 The Latin American Pharmaceutical Market, 2014-2025
13.2 Latin American Pharmaceutical Market Forecast, 2015-2025

List of Tables
Table 2.1 Market Share (%) of the Global Pharmaceutical Market by Region, 2014
Table 2.2 Population Sizes of Latin American Countries/Regions and Percentage of Total Population (%), 2012
Table 3.1 The Latin American Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 3.2 Percentage (%) of Population Over 65 Years Old in Key Latin American Markets, plus Average, 2010 and 2050
Table 3.3 The Latin American Pharmaceutical Market Breakdown, Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 3.4 The Latin American Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 3.5 The Latin American OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 3.6 The Latin American Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 3.7 The Latin American Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 3.8 SWOT Analysis of the Latin American Pharmaceutical Market, 2014-2025
Table 4.1 Market Revenues ($bn) of the Six Largest Pharmaceutical Markets in Latin America, 2014
Table 4.2 The Latin American National Pharmaceutical Markets: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.3 National Market Revenues ($bn) and Latin American Market Shares (%), 2014
Table 4.4 National Market Revenues ($bn) and Latin American Market Shares (%), 2020
Table 4.5 National Market Revenues ($bn) and Latin American Market Shares (%), 2025
Table 5.1 Brazilian National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.2 Brazilian National Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.3 Brazilian Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.4 Brazilian OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.5 Brazilian Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.6 Brazilian Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.7 Brazilian National Market Breakdown: Revenue (Currency Adjusted) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 6.1 Mexican National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 6.2 Mexican National Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 6.3 Mexican Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 6.4 Mexican OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 6.5 Mexican Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 6.6 Mexican Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 6.7 Mexican National Market Breakdown: Revenue (Currency Adjusted) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 7.1 Venezuelan National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 7.2 Venezuelan National Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 7.3 Venezuelan Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 7.4 Venezuelan OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 7.5 Venezuelan Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 7.6 Venezuelan Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 8.1 Argentine National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 8.2 Argentine National Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 8.3 Argentine Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 8.4 Argentine OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 8.5 Argentine Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 8.6 Argentine Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 8.7 Argentine National Market Breakdown: Revenue (Currency Adjusted) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 9.1 Colombian National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 9.2 Colombian National Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 9.3 Colombian Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 9.4 Colombian OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 9.5 Colombian Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 9.6 Colombian Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 9.7 Colombian National Market Breakdown: Revenue (Currency Adjusted) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 10.1 Branded Market Share (%) of Generic Drugs Market by Value, 2014
Table 10.2 Chilean National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 10.3 Chilean National Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 10.4 Chilean Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 10.5 Chilean OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 10.6 Chilean Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 10.7 Chilean Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 10.8 Chilean National Market Breakdown: Revenue (Currency Adjusted) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 11.1 The Rest of the Latin American Pharmaceutical Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 11.2 Rest of the Latin American Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 11.3 Rest of the Latin American Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 11.4 Rest of the Latin American OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 11.5 Rest of the Latin American Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 11.6 Rest of the Latin American Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025
Table 12.1 Sanofi S.A Total Revenue ($bn) and Latin American Revenue ($bn) and AGR (%), 2013-2014
Table 12.2 Novartis Total Revenue ($bn) and Latin American Revenue ($bn) and AGR (%), 2013-2014
Table 13.1 The Latin American National Pharmaceutical Markets: Revenue ($bn), AGR (%), 2014-2015
Table 13.2 The Latin American Pharmaceutical Market: Revenue ($bn), AGR (%), CAGR (%), 2014-2025

List of Figures
Figure 1.1 Population Sizes of Latin American Countries/Regions by Percentage (%), 2013
Figure 1.2 Key Markets within the Latin American Pharmaceutical Market
Figure 1.3 Key Product Types within the Latin American Pharmaceutical Market
Figure 2.1 Market Shares (%) of Pharmaceutical Market by Region, 2014
Figure 2.2 Population Sizes of Latin American Countries/Regions by Percentage (%), 2012
Figure 3.1The Latin American Pharmaceutical Market: Revenue ($bn) and AGR (%), 2014-2025
Figure 3.2 Population Pyramid for Latin America, 2010
Figure 3.3 Population Pyramid for Latin America, 2025
Figure 3.4 The Latin American Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 3.5 The Latin American OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 3.6 The Latin American Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 3.7 The Latin American Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 4.1 Market Revenues ($bn) of Six Largest Pharmaceutical Markets in Latin America plus Rest of Latin America, 2014
Figure 4.2 Market Revenues ($bn) of Six Largest Pharmaceutical Markets in Latin America plus Rest of Latin America, 2014
Figure 4.3 Market Revenues ($bn) of Six Largest Pharmaceutical Markets in Latin America plus Rest of Latin America, 2020
Figure 4.4 Market Revenues ($bn) of Six Largest Pharmaceutical Markets in Latin America plus Rest of Latin America, 2025
Figure 5.1 Brazilian National Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 5.2 Brazilian Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 5.3 Brazilian OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 5.4 Brazilian Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 5.5 Brazilian Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 6.1 Mexican National Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 6.2 Mexican Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 6.3 Mexican OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 6.4 Mexican Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 6.5 Mexican Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 7.1 Venezuelan National Pharmaceutical Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 7.2 Venezuelan Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 7.3 Venezuelan OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 7.4 Venezuelan Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 7.5 Venezuelan Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 8.1 Argentine National Pharmaceutical Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 8.2 Argentine Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 8.3 Argentine OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 8.4 Argentine Biosimilars Market: Revenue (Constant Currencies) $bn) and AGR (%), 2014-2025
Figure 8.5 Argentine Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 9.1 Colombian National Pharmaceutical Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 9.2 Colombian Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 9.3 Colombian OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 9.4 Colombian Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 9.5 Colombian Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 10.1 Branded Market Share (%) of Generic Drugs Market by Value, 2014
Figure 10.2 Chilean National Pharmaceutical Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 10.3 Chilean Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 10.4 Chilean OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 10.5 Chilean Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 10.6 Chilean Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 11.1 Rest of the Latin American National Pharmaceutical Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 11.2 Rest of the Latin American Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 11.3 Rest of the Latin American OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 11.4 Rest of the Latin American Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 11.5 Rest of the Latin American Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025
Figure 13.1 The Latin American National Pharmaceutical Markets: Revenue ($bn), 2014-2015
Figure 13.2 The Latin American Pharmaceutical Market: Revenue ($bn), 2014-2025



Companies Listed
Abbott Laboratories
Aspen Pharmaceuticals
Bago
Bayer AG
Bioceres
Biocon
Celltrion
CFR Pharmaceuticals
EMS S.A
Genfar
Germed
GlaxoSmithKline
Hospira
Janssen RA
Laboratorio Teuto Brasileiro.
Laboratorios Bernabo
Laboratorios Kendrick
LaFrancol
LeGrand
Medley
Merck AG
Novartis
Orygen
Pemex
Pfizer
Priobiomed
Roemmers
Sandoz
Sanofi S.A
Shanghai CP Goujian
Takeda

Other Organisations Mentioned In The Report
Bolivarian Alliance for the Peoples of Our America (ALBA)
Brazilian Ministry of Health
Brazilian Unified Health System
Chilean Institute of Public Health
COFEPRIS
Instituto de Seguridad y Servicios Sociales de los Trabajadoes del Estad (ISSSTE)
Instituto Mexicano del Seguro Social (IMSS)
Instituto Venezolano de los Seguros Sociales (IVSS)
Mercosur
National Drugs Agency (ANAMED)
Pan American Health Organisation
Sistema General de Seguridad Social en Salud
The Andean Community (CAN)
The Pacific Alliance
The Union of South American Nations (USAN)
Trans-Pacific Partnership
United Nations Department of Economic and Social Affairs
Venezuelan Ministry of Popular Power for Health

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.